Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Inc., and Millennium Pharmaceuticals, Inc.

Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Lung Cancer, Genitourinary Malignancies, and Gynecologic Malignancies


Release Date: December 30, 2018
Expiration Date: December 30, 2019
Media: Internet - based

Activity Overview

This online Physicians’ Education Resource, LLC® activity, Cancer Summaries and Commentaries™: Update from Munich: Advances in the Treatment of Lung Cancer, Genitourinary Malignancies, and Gynecologic Malignancies, is designed to update physicians on data presented at the European Society for Medical Oncology (ESMO) 2018 Congress, which took place October 19-23, 2018, in Munich, Germany. During this online activity, the program faculty, David Gandara, MD, Bernard Escudier, MD, and Richard Penson, MD, MRCP, will each review 3 abstracts within the fields of lung cancer, genitourinary malignancies, and gynecologic malignancies, respectively. These abstracts were chosen as the most clinically relevant to facilitate integration of cutting-edge data into practice. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participating

  • Identify key ongoing clinical trial designs that evaluated novel strategies in patients with lung cancer, genitourinary malignancies, and gynecologic malignancies
  • Understand recent cutting-edge clinical trial results that impact treatment of patients with lung cancer, genitourinary malignancies, and gynecologic malignancies, and how to apply these results of recent clinical trials to your practice
  • Hear expert perspectives on the latest evidence from the ESMO 2018 Congress, and how these data affect evolving treatment paradigms for patients

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Inc., and Millennium Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward ex-US medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with lung cancer, genitourinary cancers, and/or gynecologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer, genitourinary cancers, and/or gynecologic malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe clinical study designs from recently reported and ongoing trials evaluating novel strategies for the management of patients with lung cancer, genitourinary malignancies, and gynecologic malignancies
  • Detail results from recent practice-changing clinical trials that evaluated novel strategies for the treatment of lung cancer, genitourinary malignancies, and gynecologic malignancies
  • Place recent evidence into the context of evolving treatment paradigms for the care of patients with lung cancer, genitourinary malignancies, and gynecologic malignancies

Faculty, Staff, and Planners' Disclosures

Faculty

Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Institut Gustave Roussy, Villejuif
Paris, France
 
 

Disclosures: Grant/Research Support: BMS, Novartis; Consultant: BMS, Pfizer, Novartis, Ipsen, EUSA, Aveo, Roche

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant/Research Support: AstraZeneca/Medi, Genentech; Consultant: AstraZeneca, Celgene, Genentech, Guardant Health, Lilly, Liquid Genomics

Richard T. Penson, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology, Medicine
Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support: Array BioPharma, AstraZeneca, Cerulean, Vascular Biogenics, Eisai, Merck, Regeneron, Sanofi-Aventis; Scientific Advisory Board: AstraZeneca, Clovis, Eisai, Merck, Mersona, Sutro Biopharma, Vascular Biogenics; Other Support: DSMB: AbbVie

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By